4594 — BrightPath Biotherapeutics Co Share Price
0.000.00%
Last trade - 00:00- ¥4bn
- ¥3bn
- ¥0m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.24 | ||
| Price to Tang. Book | 3.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 39,060.13 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -84.82% | ||
| Return on Equity | -108.09% | ||
| Operating Margin | -1081803.19% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 11.3 | 2.5 | 15.41 | 5.28 | 0.07 | n/a | n/a | -78.47% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 8th, 2003
- Public Since
- October 22nd, 2015
- No. of Shareholders
- 26,506
- No. of Employees
- 24
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 91,791,299
- Address
- 7F, Kojimachi Central Bldg, CHIYODA-KU, 102-0083
- Web
- https://www.brightpathbio.com/
- Phone
- +81 444403939
- Auditors
- Ernst & Young ShinNihon LLC
Upcoming Events for 4594
Similar to 4594
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
Chiome Bioscience
Tokyo Stock Exchange
Chordia Therapeutics
Tokyo Stock Exchange
FAQ
What is the BrightPath Biotherapeutics Co share price?
As of Today at 19:41 UTC, shares in BrightPath Biotherapeutics Co are trading at ¥40. This share price information is delayed by 15 minutes.
How has the BrightPath Biotherapeutics Co share price performed this year?
Shares in BrightPath Biotherapeutics Co last closed at ¥40 and the price had moved by -32.2% over the past 365 days. In terms of relative price strength the BrightPath Biotherapeutics Co share price has underperformed the Nikkei 225 Index by -28.55% over the past year.
What are the analyst and broker recommendations for BrightPath Biotherapeutics Co?
There is no consensus recommendation for this security.
Find out moreWhat is the BrightPath Biotherapeutics Co dividend yield?
BrightPath Biotherapeutics Co does not currently pay a dividend.
Does BrightPath Biotherapeutics Co pay a dividend?
BrightPath Biotherapeutics Co does not currently pay a dividend.
When does BrightPath Biotherapeutics Co next pay dividends?
BrightPath Biotherapeutics Co does not currently pay a dividend.
How do I buy BrightPath Biotherapeutics Co shares?
To buy shares in BrightPath Biotherapeutics Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BrightPath Biotherapeutics Co?
As of the previous close price of ¥40, shares in BrightPath Biotherapeutics Co had a market capitalisation of ¥4bn.
Where are BrightPath Biotherapeutics Co shares listed?
Here are the trading details for BrightPath Biotherapeutics Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4594
What kind of share is BrightPath Biotherapeutics Co?
Based on an overall assessment of its quality, value and momentum BrightPath Biotherapeutics Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BrightPath Biotherapeutics Co share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the BrightPath Biotherapeutics Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BrightPath Biotherapeutics Co. Over the past six months, its share price has outperformed the Nikkei 225 Index by +2.97%.
As of the last closing price of ¥40, shares in BrightPath Biotherapeutics Co were trading -18.97% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BrightPath Biotherapeutics Co PE Ratio?
The BrightPath Biotherapeutics Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BrightPath Biotherapeutics Co?
BrightPath Biotherapeutics Co's management team is headed by:
- Kenichi Nagai - PRE
- Yutaka Waki - COO
- Akira Yamada - DRC
- Hirotaka Takeuchi - IND